Spectrophotometric determination of valsartan using p-chloranilic Acid as π-acceptor in pure and in Dosage forms by Mallegowda, S. M. et al.
  
 
 
 
 
Journal of Applied Pharmaceutical Science Vol. 3 (01), pp. 113-116, January, 2013 
Available online at http://www.japsonline.com 
DOI: 10.7324/JAPS.2013.30122 
ISSN 2231-3354   
 
Spectrophotometric Determination of Valsartan using p-Chloranilic  
Acid as π-Acceptor in Pure and in Dosage Forms 
 
S. M. Mallegowda, H. N. Deepakumari and H. D. Revanasiddappa* 
Department of Chemistry, University of Mysore, Manasagangotri, Mysore-570 006, India. 
 
 
 
 
ARTICLE INFO 
 
 
 
ABSTRACT 
 
Article history: 
Received on: 10/12/2012 
Revised on: 29/12/2012 
Accepted on: 10/01/2013 
Available online: 28/01/2013 
 
 
 
 
 
 
 
 
 
 
 
 
The aim of this work was to develop a simple, sensitive and extraction free spectrophotometric method for the 
quantitative estimation of valsartan in both pure and in pharmaceutical preparations. The developed method is 
based on the charge transfer complexation reaction between valsartan (VRT) as n- electron donor and p-
chloranilic acid (p-CA) as π-acceptor. VRT reacts with p-CA in methanol to produce a bright pink colored 
complex with a maximum absorption at 530 nm. Beer's law was obeyed in the concentration range of 5-50 
µg/mL. The linear regression equation of the calibration graph is A = 0.0081+0.0092C with a regression 
coefficient (r) of 0.9976 (n = 7). The molar absorptivity is calculated to be 2.06 × 103 L mol–1 cm–1 and the 
Sandell sensitivity is 0.1025 μg cm–2. The limits of detection (LOD) and quantitation (LOQ) values are 
calculated according to ICH guidelines. The method developed is successfully applied to the determination of 
VRT in dosage forms. 
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INTRODUCTION 
 
Chemically valsartan (VRT) is (S)-3-methyl-2-(N-{[2'-
(2H -1 ,2 ,3 ,4-tetrazol-5-yl) biphenyl -4-yl] methyl} pentanamido) 
butanoic acid (Fig. 1) has an empirical formula of C24H29N5O3 is a 
potent angiotensin receptor π antagonist with particularly high 
affinity for the type I (AT1) angiotensin receptor. By blocking the 
action of angiotensin, valsartan dilates blood vessels and reduces 
blood pressure (Marks, 2007). 
 
 
 
Fig. 1:  Structure of valsartan. 
 
Several analytical methods have been reported for the 
determination of VRT in combination with other anti‐ hypertensive  
agents in pharmaceutical formulations. Very few methods have 
been appeared in the literature for the determination of valsartan 
individually, those include high performance liquid chromate-
graphy (Zarghi et al., 2008, Li et al., 2000, Gonzales et al., 2000, 
Francotte et al.,1996, Parambi et al., 2011), RP-HPLC (Vinzuda et 
al., 2010, Manoranjani  et al., 2011, Patnaik et al., 2011), UV- and 
second derivative-spectrophotometric and LC method (Tatar et al., 
2002), HPLC with UV Detection (Piao  et al.,2008) and uv-
spectrophotometry (Gupta et al., 2010) and spectrofluorimetric 
determination of losartan and valsartan in human urine (Gagigal et 
al., 2001) and simultaneous determination of valsartan and 
hydrochlorothiazide in tablets by first-derivative ultraviolet 
spectrophotometry and LC [Satana et al., 2001]. The VRT is not yet 
appeared in any pharmacopoeia either alone or in combinations 
with other drugs.  
The purpose of the present work is the development of a 
simple spectrophotometric method for the determination of VRT in 
bulk and in pharmaceutical formulations through the formation of 
charge transfer complexation reaction between valsartan (VRT) as 
n- electron donor and p-chloranilic acid (p-CA) as π-acceptor. 
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MATERIALS AND METHODS 
 
 Apparatus 
 Absorbance measurements for spectrophotometric 
analysis were performed using a Systronics Model 166 digital 
spectrophotometer provided with 1-cm matched quartz cells.  
 
Reagents and standards 
 Analytical reagent grade chemicals and reagents were 
used. 
 
p-chloranilic acid (0.05 %, w/v)  
 It was freshly prepared by dissolving 0.05 g p-chloranilic 
acid (Rolex, Mumbai, India) in 100 mL acetone. 
 
Standard VRT solution 
 The pure grade VRT, certified to be 99.99% was 
received from Cipla India Ltd., Mumbai, India, as a gift sample 
and was used as such. A stock standard solution equivalent to 100 
µg/mL of VRT was prepared by dissolving 10 mg of the pure drug 
in 100 mL methanol. 
 Pharmaceutical formulations of VRT such as VALZAAR 
[Torrent], DIOVAN [Novartis Pharma] were purchased from local 
markets. 
 
Procedure for calibration graph 
 Accurately measured aliquots of standard solution of 
VRT (100µg/mL) corresponding to 0.5, 1.0, 1.5, 2.0, 
…………..5.0 mL were transferred into a series of 10 mL 
calibrated flasks using a micro burette. To this solution was added 
3.5 mL 0.05 % p-CA, then shake well and the contents were 
diluted to the mark with methanol and mixed well. The absorbance 
of the bright pink colored complex was measured at 530 nm after 5 
min against the reagent blank prepared similarly, but without drug 
content.  
 
Procedure for dosage forms 
 In order to determine the contents of VRT in commercial 
dosage forms (label claim: 40 and 80 mg tablet), the contents of 
ten tablets were weighed accurately and ground into a fine powder. 
An amount of powder equivalent to 10 mg of VRT was accurately 
weighed and transferred into two separate 100mL calibrated flasks 
and 30 mL of methanol was added. The content was shaken for 
about 30 min; the volume was diluted to the mark with methanol 
and mixed well and filtered using a Whatman no.41 filter paper. 
The filtrate containing VRT at a concentration 100 µg/mL was 
subjected to analysis by the procedure described above. 
 
RESULTS AND DISCUSSION 
 
Chemistry of the method   
 The method developed involves charge-transfer complex 
formation between the basic nitrogenous VRT as n-donor and p-
chloranilic acid (p-CA) in polar solvent as π-acceptor. The formed 
charge transfer (C-T) complex was subsequently dissociated into 
radical anions, which are colored species. The absorbance of the 
colored complex was measured at 530 nm, and it was observed as 
shown in the following equation:  
 
 
Thus, p-CA was used as reagent in the proposed method 
for the estimation of VRT. The possible reaction pathway for VRT 
- p-CA complex is shown in scheme1. 
 
 
 
Scheme. 1: Proposed reaction scheme. 
 
 The influence of various factors on the formation of 
charge-transfer complex viz., reagent concentration, reaction time 
and stability of the colored complex were studied and maintained 
throughout the experiment to determine the quantity of VRT in 
bulk and in dosage forms. Highest absorbance values were 
obtained with 3.5 mL of 0.05 % p-CA, which remained unaffected 
by further addition of p-CA. Thus, 3.5 mL of the reagent was used 
for the determination in the developed method. It was observed 
that the formed complex was stabilized within 5 min in the 
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developed method. The color of the C-T complex remained stable 
at room temperature (27 ± 3 ºC) for a period of 2 h.  
 
Method validation  
 The developed method was validated in terms of linearity 
and sensitivity, limit of detection (LOD) and limit of quantitation 
(LOQ), precision, accuracy, selectivity and recovery following the 
ICH guidelines (International Conference On Harmonization, 
guidelines). 
 
Linearity, sensitivity, limits of detection and quantification  
 A calibration graph was constructed using a standard 
solution of VRT at respective wavelength and concentration of 
VRT in the ranges is given in Table 1. Under the optimum 
experimental conditions, a linear relationship existed between the 
absorbance and concentration of the drugs. The regression analysis 
of the calibration curve using the method of least-squares was 
made to calculate the slope (b), intercept (a) and correlation co-
efficient (r) values are presented in Table 1. The optical 
characteristics such as absorption maxima, Beer’s law limit, molar 
absorptivity and Sandell’s sensitivity value of the method are also 
given in Table 1.  
 
Table. 1: Analytical and regression parameters of the proposed methods. 
*y=a+bx, where c is the concentration of VRT in µg/mL and y is the 
absorbance at the respective λmax., Sa is the standard deviation of the intercept, 
Sb is the standard deviation of the slope. 
 
Intra and inter-day precision and accuracy  
 The accuracy of an analytical method expresses the 
closeness between the proposed method and reference method. 
Further, the accuracy and precision (intra-day) of the proposed 
method were evaluated by replicate analysis (n=5) of calibration 
standards at three different concentration levels in the same day. 
Precision and accuracy of inter-day were measured by performing 
the calibration standards at cited three concentrations on five 
consecutive days. Both precision and accuracy were based on the 
calculated percent relative standard deviation (RSD, %)                    
and   percent   relative   error   (RE, %)   values,   respectively   for  
 
 
 
 
 
 
thedeveloped method were found to be satisfactory. The analytical 
results obtained from this investigation are summarized in Table 2. 
 
Application to analysis of pharmaceutical samples  
 The validity of the proposed method was ascertained by 
the statistical comparison of the results obtained by a reference 
method (Patnaik et al., 2011) with the proposed method by 
applying Student’s t-test for accuracy and F- test for precision in 
some commercial formulations.  
 The results were compared with those of the reported 
method. Statistical analysis of the results using the Student’s-t and 
F-tests revealed no significant difference between the reported 
method at the 95% confidence level with respect to accuracy and 
precision (Table 3). 
 
Table. 3: Results of determination of VRT in tablets and statistical comparison 
with the reference method. 
Tablet 
brand 
Name 
Nominal 
amount mg per 
tablet 
Found*(% of nominal amount ± SD) 
Reference method Proposed method 
VALZAARa 40 100.88±0.48 
99.62±0.704 
t = 1.68, 
F = 2.15 
DIOVANb 80 100.80 ±0.46 
100.38±0.854 
t = 0.51, 
F = 3.45 
Marketed by: a. [Torrent], b. [Novartis Pharma] 
*Mean value of five determinations 
Tabulated t and F-values at 95 % confidence level are 2.77 and 6.39, 
respectively. 
 
Recovery study 
 To test the applicability of the proposed method, 
recovery experiments were carried out by standard addition 
method. In this study, pre-analyzed tablet powder was spiked with 
pure drug at three different concentrations and the total was found 
by the proposed method. Each determination was repeated three 
times. The recovery of the pure drug added was quantitative and 
revealed that co-formulated substances did not interfere in the 
determination. The results of recovery study are compiled in Table 
4. 
 
Table. 4:  Results of recovery experiments via the standard addition technique. 
Tablet 
brand 
name 
VRT  
mg per 
tablet 
Pure VRT 
added, 
µg/mL 
Total 
found 
µg/mL 
Pure VRT 
recovered* 
% ± SD 
VALZ
AARa 40 
20 20.02 100.22 ± 0.77 
30 29.83 99.16 ± 0.88 
40 39.85 99.49 ±0.46 
DIOV
ANb 80 
20 19.91 99.13±0.77 
30 30.20 100.98±0.85 
40 40.31 101.03±0.95 
a. * Mean value of three determinations. 
b. Marketed by: a. [Torrent], b. [Novartis Pharma] 
 
 
 
 
 
 
 
Parameter Method  
λmax nm 530 
Beer’s law range (µg/mL ) 5.0 – 50 
Molar absorptivity (ε), (L mol-1cm-1) 2.06 x 10 3 
Sandell sensitivity ( µg cm-2) 0.1025 
Intercept (a) 0.0081 
Slope (b) 0.0092 
Correlation coefficient (r) 0.9976 
Sa 0.0170 
Sb 0.0004 
LOQ ( µg/mL ) 1.1169 
LOD ( µg/mL ) 0.3686 
Table. 2:  Evaluation of intra-day and inter-day accuracy and precision results. 
 VRT taken,               
μg/mL 
intra-daya inter-dayb 
VRT foundc, μg/mL Precisiond Accuracy e VRT foundc, μg/mL Precisiond Accuracy e 
Method 
10 9.93±0.10 1.02 0.66 9.97±0.25 2.50 0.21 
20 19.97±0.06 0.30 0.17 19.84±0.13 0.63 0.81 
40 40.07±0.33 0.83 0.18 39.79±0.29 0.74 0.52 
Mean value of five determinations, b. Mean value of five determinations, c. Mean value of three determinations, d. Relative standard deviation (%), e. Bias%: 
(found-taken/taken)×100. 
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CONCLUSION 
 
 The proposed method is simple and sensitive and in 
addition, the method has wider linear dynamic range with good 
accuracy and precision which could be applied for the 
determination of valsartan in bulk drug and dosage forms. From 
the calculated t- and F-values at the 95 % confidence level, it is 
clear that, the results obtained by the proposed method are in good 
agreement with those obtained by the reference method. The small 
values of R.E and R.S.D. indicate the reliability, accuracy and 
precision of suggested procedure. The results obtained in Table 3 
are considered to be of high accuracy and can be successfully 
applied to the routine assay of valsartan in pharmaceutical 
formulations. 
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